Business Wire
04 Aug 2026, 10:45 UTC · 1h ago
Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Business Wire
04 Aug 2026, 10:45 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Pfizer raised its full-year 2026 revenue guidance by $500 million at the midpoint. — Upward revisions to annual revenue guidance typically signal stronger-than-expected demand and growth, driving stock price appreciation.
+0.60Pfizer reaffirmed its full-year 2026 Adjusted diluted EPS guidance. — Reaffirming guidance is a neutral signal, suggesting the company is on track but not accelerating profitability beyond prior expectations.
+0.10The company's EPS guidance absorbs a $0.10 per share impact related to the Innovent Biologics transaction. — A specific transactional cost creating a drag on earnings is a minor negative, though likely already factored into the reaffirmed guidance.
-0.10Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company reported strong quarterly results and raised its full-year revenue guidance.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
1h ago
